Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XBIO 
Xenetic Biosciences Inc (XBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/10/2025: XBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.37% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.05M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 2.29 | 52 Weeks Range 2.20 - 5.27 | Updated Date 06/30/2025 |
52 Weeks Range 2.20 - 5.27 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -142.03% | Operating Margin (TTM) -158.85% |
Management Effectiveness
Return on Assets (TTM) -31.93% | Return on Equity (TTM) -53.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 883312 | Price to Sales(TTM) 2.34 |
Enterprise Value 883312 | Price to Sales(TTM) 2.34 | ||
Enterprise Value to Revenue 0.34 | Enterprise Value to EBITDA 1.03 | Shares Outstanding 1542140 | Shares Floating 1182805 |
Shares Outstanding 1542140 | Shares Floating 1182805 | ||
Percent Insiders 19.05 | Percent Institutions 7.61 |
Analyst Ratings
Rating 1 | Target Price 40 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xenetic Biosciences Inc
Company Overview
History and Background
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapeutics and novel biologics. Founded in 2003, they initially focused on drug delivery technology before shifting towards developing novel treatments for a range of diseases.
Core Business Areas
- OncoHist Program: Focuses on novel personalized oncology therapeutics leveraging the body's inherent defense mechanisms to selectively kill tumor cells.
- Blood Coagulation: Developing novel treatments for hemophilia.
- Lipid Disorders: Researching treatment options for lipid-related health issues.
Leadership and Structure
Xenetic Biosciences is led by a management team with experience in biotechnology and pharmaceutical development. The organizational structure includes departments dedicated to research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- OncoHist Platform: A technology to develop tumor-specific antibodies. The market share is difficult to quantify precisely due to the early stage of development and the highly competitive oncology therapeutic market. Competitors include major pharmaceutical companies developing personalized cancer treatments.
- PSA-EPO: A pre-clinical treatment for anemia. This product has no market share and is in pre-clinical trials. Competitors would include Amgen's Epogen and other erythropoietin stimulating agents.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The market is driven by unmet medical needs and the aging global population.
Positioning
Xenetic Biosciences is a relatively small player in the biopharmaceutical industry, focusing on niche areas with potential for innovation. Its competitive advantage lies in its proprietary drug delivery platforms and its approach to developing personalized oncology therapeutics.
Total Addressable Market (TAM)
The TAM for personalized oncology therapeutics is estimated to be in the tens of billions of dollars. Xenetic Biosciences aims to capture a portion of this market through its novel OncoHist platform.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery platforms
- Innovative approach to personalized oncology
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Small size compared to competitors
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results leading to regulatory approval
- Expansion into new therapeutic areas
- Increasing demand for personalized medicine
Threats
- Competition from larger pharmaceutical companies
- Failure to achieve successful clinical trial outcomes
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRTX
- LLY
- GILD
Competitive Landscape
Xenetic Biosciences faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its proprietary technology and focus on niche therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Xenetic Biosciences' growth has been primarily driven by its research and development activities and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing the OncoHist program through clinical trials and securing partnerships for technology development.
Summary
Xenetic Biosciences is a biopharmaceutical company focusing on novel therapeutic platforms, mainly in personalized oncology. While their proprietary technologies are promising, their small size and limited resources present challenges. Successful clinical trials and strategic partnerships are critical for their future growth. They face considerable competition from larger, more established pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated based on publicly available information and may not be precise. All data are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenetic Biosciences Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-06-30 | CFO, COO, Interim CEO & Corporate Secretary Mr. James F. Parslow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.xeneticbio.com |
Full time employees 2 | Website https://www.xeneticbio.com | ||
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.